139 related articles for article (PubMed ID: 37929639)
1. Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.
Pigors M; Patzelt S; Reichhelm N; Dworschak J; Khil'chenko S; Emtenani S; Bieber K; Hofrichter M; Kamaguchi M; Goletz S; Köhl G; Köhl J; Komorowski L; Probst C; Vanderheyden K; Balbino B; Ludwig RJ; Verheesen P; Schmidt E
J Pathol; 2024 Feb; 262(2):161-174. PubMed ID: 37929639
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner.
Natsuga K; Nishie W; Shinkuma S; Ujiie H; Nishimura M; Sawamura D; Shimizu H
J Immunol; 2012 Jun; 188(11):5792-9. PubMed ID: 22523387
[TBL] [Abstract][Full Text] [Related]
3. Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model.
Ujiie H; Shibaki A; Nishie W; Shinkuma S; Moriuchi R; Qiao H; Shimizu H
Clin Immunol; 2012 Feb; 142(2):167-75. PubMed ID: 22044750
[TBL] [Abstract][Full Text] [Related]
4. Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models.
Ujiie H; Yoshimoto N; Natsuga K; Muramatsu K; Iwata H; Nishie W; Shimizu H
Front Immunol; 2019; 10():1410. PubMed ID: 31275329
[TBL] [Abstract][Full Text] [Related]
5. Anti-collagen XVII single-chain Fv antibody blocks the autoimmune reaction mediated by pathogenic autoantibodies in bullous pemphigoid.
Wu Y; Sun NN; Dang EL; Jin L; Liu ZF; Zhang W; Yang LT; Wang G
J Dermatol Sci; 2013 Oct; 72(1):25-31. PubMed ID: 23827201
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies of non-inflammatory bullous pemphigoid hardly deplete type XVII collagen of keratinocytes.
Imafuku K; Iwata H; Kamaguchi M; Izumi K; Natsuga K; Ujiie H; Nishie W; Shimizu H
Exp Dermatol; 2017 Dec; 26(12):1171-1174. PubMed ID: 28266727
[TBL] [Abstract][Full Text] [Related]
7. Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.
Karsten CM; Beckmann T; Holtsche MM; Tillmann J; Tofern S; Schulze FS; Heppe EN; Ludwig RJ; Zillikens D; König IR; Köhl J; Schmidt E
Front Immunol; 2018; 9():488. PubMed ID: 29599777
[TBL] [Abstract][Full Text] [Related]
8. High Expression of Collagen XVII Compensates for its Depletion Induced by Pemphigoid IgG in the Oral Mucosa.
Kamaguchi M; Iwata H; Ujiie H; Natsuga K; Nishie W; Kitagawa Y; Shimizu H
J Invest Dermatol; 2018 Aug; 138(8):1707-1715. PubMed ID: 29530535
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning of a cDNA encoding the porcine type XVII collagen noncollagenous 16 A domain and localization of the domain to the upper part of porcine skin basement membrane zone.
Xu L; Olivry T; Chan LS
Vet Dermatol; 2004 Jun; 15(3):146-51. PubMed ID: 15214950
[TBL] [Abstract][Full Text] [Related]
10. What's new in bullous pemphigoid.
Ujiie H; Shibaki A; Nishie W; Shimizu H
J Dermatol; 2010 Mar; 37(3):194-204. PubMed ID: 20507382
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
Front Immunol; 2019; 10():1934. PubMed ID: 31474998
[TBL] [Abstract][Full Text] [Related]
12. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
13. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen.
Ujiie H; Shibaki A; Nishie W; Sawamura D; Wang G; Tateishi Y; Li Q; Moriuchi R; Qiao H; Nakamura H; Akiyama M; Shimizu H
J Immunol; 2010 Feb; 184(4):2166-74. PubMed ID: 20089696
[TBL] [Abstract][Full Text] [Related]
14. Macropinocytosis of type XVII collagen induced by bullous pemphigoid IgG is regulated via protein kinase C.
Iwata H; Kamaguchi M; Ujiie H; Nishimura M; Izumi K; Natsuga K; Shinkuma S; Nishie W; Shimizu H
Lab Invest; 2016 Dec; 96(12):1301-1310. PubMed ID: 27775687
[TBL] [Abstract][Full Text] [Related]
15. Deletion of the major bullous pemphigoid epitope region of collagen XVII induces blistering, autoimmunization, and itching in mice.
Hurskainen T; Kokkonen N; Sormunen R; Jackow J; Löffek S; Soininen R; Franzke CW; Bruckner-Tuderman L; Tasanen K
J Invest Dermatol; 2015 May; 135(5):1303-1310. PubMed ID: 25310407
[TBL] [Abstract][Full Text] [Related]
16. Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.
Ujiie H; Sasaoka T; Izumi K; Nishie W; Shinkuma S; Natsuga K; Nakamura H; Shibaki A; Shimizu H
J Immunol; 2014 Nov; 193(9):4415-28. PubMed ID: 25261486
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin.
Sitaru C; Schmidt E; Petermann S; Munteanu LS; Bröcker EB; Zillikens D
J Invest Dermatol; 2002 Apr; 118(4):664-71. PubMed ID: 11918714
[TBL] [Abstract][Full Text] [Related]
18. Epitope-Dependent Pathogenicity of Antibodies Targeting a Major Bullous Pemphigoid Autoantigen Collagen XVII/BP180.
Wada M; Nishie W; Ujiie H; Izumi K; Iwata H; Natsuga K; Nakamura H; Kitagawa Y; Shimizu H
J Invest Dermatol; 2016 May; 136(5):938-946. PubMed ID: 26827765
[TBL] [Abstract][Full Text] [Related]
19. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain.
Kromminga A; Sitaru C; Meyer J; Arndt R; Schmidt E; Christophers E; Bröcker EB; Zillikens D
J Dermatol Sci; 2002 Jan; 28(1):68-75. PubMed ID: 11916132
[TBL] [Abstract][Full Text] [Related]
20. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
Fairley JA; Fu CL; Giudice GJ
J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
